Skip to main content
. 2019 Jul 9;9(17):4878–4892. doi: 10.7150/thno.36254

Figure 7.

Figure 7

Graph abstract: the anti-cancer mechanism of brigatinib in CRC cells. Brigatinib enhances interaction of USP5 with ORP8 to facilitate ORP8 accumulation by attenuating ubiquitination degradation, resulting in ORP8-induced ER stress. Meanwhile, ER-phagy is stimulated to relieve ER stress in brigatinib-treated CRC cells.